Background and Objectives: Erythermalgia is a rare disorder characterized by erythema, edema, elevated skin temperature, and burning pain of the hands and/or feet. The etiology of primary erythermalgia is idiopathic while secondary erythermalgia is associated with autoimmune and rheumatologic factors. Symptoms are typically refractory to medical management. We report the use of epidural bupivacaine as a treatment option for secondary erythermalgia.
T he etiology of erythermalgia, previously referred to as erythromelalgia, is unknown. It is a rare disorder characterized by erythema, edema, elevated skin temperature, and burning pain involving the hands and/or feet. Erythermalgia is often refractory to medical management and can contribute to significant disability, including amputation. A case of secondary erythermalgia involving the lower extremities, successfully treated with epidural bupivacaine, is presented.
Case Report
A 28-year-old woman presented with a 19-day history of erythema, edema, and severe burning pain of her upper and lower extremities. Her symptoms involved her wrists, fingers, ankles, and toes bilaterally, with recent progression to her elbows and knees. Only immersing her legs in ice water lessened her pain. She reported a verbal analog pain score of 8 (VAPS; 0 ϭ no pain, 10 ϭ worst pain imaginable) and was unable to ambulate due to the progression of these symptoms in her lower extremities. Past medical history was unremarkable. Laboratory tests revealed negative antinuclear antibody titers, strep screen, rheumatoid factor, antidouble-stranded DNA, antistreptolysin antibody titers, sedimentation rate, and complement reactive protein, as well as a platelet count of 240,000/mL. She was treated with penicillin, aspirin, indomethacin, acetaminophen, hydrocodone, alprazolam, and prednisone, which provided mild improvement of wrist, elbow, and knee discomfort.
The patient was admitted for pain management and evaluation. She was diagnosed with erythromelalgia and treated with salsalate 1,500 mg orally twice daily, methylprednisolone 15 mg intravenously (IV) every 6 hours, followed by prednisone 60 mg every day, cyproheptadine 4 mg orally twice daily, and gabapentin 900 mg orally 3 times a day without relief. The Anesthesiology Acute Pain Service (APS) evaluated the patient and placed her on IV morphine patient-controlled analgesia (PCA) with a bolus of 2 mg available every 8 minutes. She reported decreased pain in her upper extremities, but continued to experience pain relief of her lower extremities only by keeping them in contact with ice.
The patient's 15-day hospital stay was complicated by recurrent episodes of Sydenham's Chorea (likely related to rheumatic fever) as well as persistent tachycardia (believed to be caused by rheumatic carditis). She was discharged home on penicillin 250 mg orally twice daily, salsalate 3 g orally twice daily, cyproheptadine 4 g orally 3 times a day, propranolol LA 80 mg orally twice daily, morphine sulfate 200 mg orally 4 times daily, hydromorphone 2 to 4 mg orally every 4 hours as needed, prednisone 60 mg orally every day with taper, omeprazole 20 mg orally every day, and docusate 100 mg orally twice daily.
One week after discharge, she followed-up in the Multidisciplinary Pain Center (MPC) complaining of persistent severe bilateral lower extremity pain and swelling. She continued to use ice water on her feet for pain relief as well as oral morphine (now at 300 mg orally 4 times daily), with minimal changes in her discomfort. Her hand discomfort was improving. On examination, the patient was sleepy but easily arousable. She had decreased range of motion of the lower extremities secondary to pain, marked pitting edema from mid-lower leg distally, allodynia, as well as increased warmth of her lower leg. She ambulated slowly with the use of a cane and was noted to have erythema involving the joints of the hands, knees, and ankles bilaterally.
Epidural analgesia was presented as an option for pain management. An L 4-5 epidural was placed and 10 mL of 0.125% bupivacaine was administered in small increments with no change in vital signs. Twenty minutes later, the patient noted complete resolution of her pain. She reported numbness and warmth in the L 3-5 distribution and in the lower extremities bilaterally. After the block, she was able to ambulate with a cane and minimal assistance. She was discharged home with the epidural catheter in place. That evening the patient noted venodilation, but less pain in her lower extremities.
The next morning in the MPC, she rated her VAPS as 2. On examination, her lower extremities were less swollen and the erythema and skin temperature changes had resolved. Ten milliliters of 0.0625% bupivacaine was again administered. Upon discharge, her VAPS remained 2 and she denied sensory change due to the epidural bupivacaine.
Three days later, she reported a VAPS of 0 and noted numbness of her lower extremities, distal to the knees. On examination there was decreased sensation distal to the mid-lower leg bilaterally, which was presumed to be caused by hypothermic nerve damage secondary to frequent ice-water analgesia. The epidural catheter was discontinued and a physical therapy regimen was initiated, as well as a gradual taper of her morphine.
The patient remained pain-free 2.5 months later. The lower extremity numbness had regressed to involve only her feet. She no longer used morphine, prednisone, omeprazole, and propranolol. The cardiac evaluation was unremarkable. Four months later, she denied pain or swelling of the extremities. Sensation was intact except for the extensor surface of her toes bilaterally. She had discontinued cyproheptadine. Nine months later she had resumed her normal routine and complained only of "fatigue" in her feet, which occurred after a hard game of softball, but sensation of the lower extremities was intact. One year later she was asymptomatic.
Discussion
Considerable confusion has surrounded the diagnosis of erythromelalgia. Smith and Allen 1 changed the name of erythromelalgia to erythermalgia to emphasize the importance of increased skin temperature in the diagnosis. They further divided the syndrome into primary or secondary based on the presence of associated disease. Erythromelalgia and erythermalgia, both primary and secondary, have often been used interchangeably. In 1990, the disorder was more clearly defined by Drenth and Michiels as 3 separate syndromes. 2 Erythromelalgia is the most common syndrome and typically presents asymmetrically; it can be diagnosed based on histopathological findings. 3 Symptoms may progress to peripheral ischemia and even gangrene. 4 A single dose of aspirin reliably provides several days of pain relief and is a pathognomonic diagnostic criterion for erythromelalgia. 4, 5 Primary erythermalgia is extremely rare. Onset frequently occurs in childhood or adolescence and has a possible genetic component. 6 Symptoms do not progress to gangrene of the extremity. Brown 7 outlined 6 criteria that must be met to obtain the diagnosis: (1) attacks of intense burning pain with congestion, vasodilatation, localized redness, and increased skin temperature; (2) symptoms that are bilateral, typically symmetrical; (3) symptoms that are aggravated by heat and exercise; (4) relief which occurs with cold, rest, and elevation of the affected limbs; (5) no associated disease; and (6) symptoms that are refractory to treatment. Secondary erythermalgia occurs primarily in association with inflammatory disturbances. 8 It is frequently associated with autoimmune and rheumatologic diseases such as scleroderma. Treatment is often refractory to current medical management.
Whether this patient had primary or secondary erythermalgia is unclear because there are no definitive laboratory tests to correlate with the physical findings, which would confirm the diagnosis. Our patient's symptoms were unresponsive to aspirin, suggesting it is unlikely she had erythromelalgia. Considering her age, gender, and rheumatologic manifestations, despite the negative rheumatologic panel, her case is most consistent with secondary erythermalgia.
Other case reports of erythermalgia have described the failure of a therapeutic response to regional block. 8 However, sympathetic block via epidural or lumbar sympathetic plexus has been a valuable way to diagnose and treat pain problems thought to be caused by sympathetic hyperactivity while increasing blood flow to the lower extremities. 9 In fact, these methods have been reported to treat peripheral vascular disease, rest pain, and rheumatoid vasculitis. In this case, the patient's symptoms were believed to be sympathetically mediated and, therefore, amenable to sympathetic block. The physiologic manifestation of her disease process was thought to be caused by decreased perfusion of the lower extremities, which resulted in ischemic pain. Thus, we chose an epidural to improve blood flow as well as provide analgesia because medical therapy had not been successful. It is possible that the epidural block was a temporizing measure that simply provided analgesia while the primary inciting events were medically treated. This patient received immediate analgesia after this block, which supports sympathetically mediated pain that was amenable to sympathetic block, providing her critical pain and symptom control. Improvement of the dermatologic manifestation and pain suggests that the epidural prevented further progression and actually caused regression of the patient's primary disease process.
Despite reports showing little benefit, this patient with secondary erythermalgia responded dramatically to the administration of epidural bupivacaine. An intermittent bolus epidural technique was used to treat the erythermalgia and provide analgesia. We conclude that epidural block in doses consistent with sympathetic block is an appropriate treatment of severely debilitating cases of erythermalgia.
